Aflibercept-Ayyh: uses, dosing, side effects & brands
Aflibercept-Ayyh is a medicine sold in the U.S. under one brand, for diabetic retinopathy and macular edema. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Diabetic Retinopathy and Macular Edema
- Available as
- Injectable
- Sold as
- Pavblu
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
How aflibercept-ayyh is dosed
From the FDA label for Pavblu (application BLA761298). Other aflibercept-ayyh products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Neovascular (Wet) Age-Related Macular Degeneration (AMD): The recommended dose for PAVBLU is 2 mg (0.05 mL of 40 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 3 months, followed by 2 mg (0.05 mL of 40 mg/mL solution) via intravitreal injection once every 8 weeks (2 months). ( 2.2 ) Although PAVBLU may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly), additional efficacy was not demonstrated in most patients when aflibercept was dosed every 4 weeks compared to every 8 weeks. Some patients may need every 4 week (monthly) dosing after the first 12 weeks (3 months). ( 2.2 ) Although not as effective as the recommended every 8 week dosing regimen, patients may also be treated with one dose every 12 weeks after one year of effective therapy. Patients should be assessed regularly. ( 2.2 ) Macular Edema Following Retinal Vein Occlusion (RVO): The recommended dose for PAVBLU is 2 mg (0.05 mL of 40 mg/mL solution) administered by intravitreal injection once every 4 weeks (approximately every 25 days, monthly). ( 2.3 ) Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR): The recommended dose for PAVBLU is 2 mg (0.05 mL of 40 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 5 injections followed by 2…
Aflibercept-Ayyh side effects
The following potentially serious adverse reactions are described elsewhere in the labeling: Hypersensitivity [see Contraindications (4.3) ] Endophthalmitis, Retinal detachments, and Retinal Vasculitis with or without Occlusion [see Warnings and Precautions (5.1) ] Increase in intraocular pressure [see Warnings and Precautions (5.2) ] Thromboembolic events [see Warnings and Precautions (5.4) ] The most common adverse reactions (≥5%) reported in patients receiving aflibercept were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Amgen Inc. at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials of the same or another drug and may not reflect the rates observed in practice. A total of 2980 adult patients treated with aflibercept constituted the safety population in eight phase 3 studies. Among those, 2379 patients were treated with the recommended dose of 2 mg. Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections with aflibercept including…
Who shouldn’t take aflibercept-ayyh
Ocular or periocular infections ( 4.1 ) Active intraocular inflammation ( 4.2 ) Hypersensitivity ( 4.3 ) 4.1 Ocular or Periocular Infections PAVBLU is contraindicated in patients with ocular or periocular infections. 4.2 Active Intraocular Inflammation PAVBLU is contraindicated in patients with active intraocular inflammation. 4.3 Hypersensitivity PAVBLU is contraindicated in patients with known hypersensitivity to aflibercept or any of the excipients in PAVBLU. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, severe anaphylactic/anaphylactoid reactions, or severe intraocular inflammation.
Every aflibercept-ayyh product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Pavblu.
What people report to the FDA about aflibercept-ayyh
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 1 reports naming aflibercept-ayyh, and the FDA flagged 100% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- eye pain1 reports
- eyelid function disorder1 reports
- headache1 reports
- visual impairment1 reports
Read these as a signal, not a rate. A report does not mean aflibercept-ayyh caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is aflibercept-ayyh?
Pavblu (Aflibercept-Ayyh) is a medication used to treat Diabetic Retinopathy, Macular Edema.
Can you take aflibercept-ayyh with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run aflibercept-ayyh against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does aflibercept-ayyh come in?
Across the brands we track, aflibercept-ayyh is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic aflibercept-ayyh?
We do not currently list a generic-labelled aflibercept-ayyh product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Aflibercept-Ayyh: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/aflibercept-ayyh
- MLA
- “Aflibercept-Ayyh: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/aflibercept-ayyh.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for aflibercept-ayyh on DailyMed (NIH) ↗.